# Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

> **NCT02458716** · PHASE1 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 26 (actual)

## Conditions studied

- Metastatic Prostate Carcinoma
- Metastatic Prostatic Adenocarcinoma
- Prostate Carcinoma Metastatic to the Bone

## Interventions

- **PROCEDURE:** Robotic Assisted Radical Prostatectomy
- **PROCEDURE:** Conventional open retropubic radical prostectomy
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)

## Key facts

- **NCT ID:** NCT02458716
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-06
- **Primary completion:** 2020-01-14
- **Final completion:** 2020-01-14
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02458716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02458716, "Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02458716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*